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Abstract
In this study, the upregulated expression level of vascular endothelial growth factor (VEGF) in a
pulmonary endothelial cell line (HPMEC-ST1.6R) infected with dengue virus serotypes 1, 2, 3, and
4 (DENV-1, -2, -3 and -4), was investigated. This cell line exhibits the major constitutive and
inducible endothelial cell characteristics, as well as angiogenic response. Infection by all four DENV
serotypes was confirmed by an observed cytopathic effect (CPE), as well as RT-PCR (reverse-
transcription polymerase chain reaction) assays. As we had previously reported, the DENV-
infected HPMEC-ST1.6R cells exhibited an elongated cytoplasmic morphology, possibly
representing a response to VEGF and activation of angiogenesis. In this study, increase in VEGF
expression level at designated time points of 0, 8, 24, 96 and 192 hours post-infection was
investigated, using a microbead-based Bio-Plex immunoassay. Increased level of VEGF expression
in infected-HPMEC-ST1.6R was detected at 8 hours post-infection. Interestingly, VEGF expression
level began to decrease up to 96 hours post-infection, after which an upsurge of increased VEGF
expression was detected at 192 hours post-infection. This profile of VEGF upregulated expression
pattern associated with DENV infection appeared to be consistent among all four DENV-serotypes,
and was not observed in mock-infected cells. In this study, the expression level of VEGF, a well-
established vascular permeabilizing agent was shown to be elevated in a time-dependent manner,
and exhibited a unique dual-response profile, in a DENV-infected endothelial cell. The experimental
observation described here provided additional insights into potential mechanism for VEGF-
mediated vascular leakage associated with DENV, and support the idea that there are potential
applications of anti-VEGF therapeutic interventions for prevention of severe DENV infections.
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Dengue fever (DF) and dengue hemorrhagic fever (DHF)
are caused by one of four closely related, but antigenically
distinct, dengue virus serotypes 1, 2, 3 or 4 (DENV-1,
DENV-2, DENV-3, and DENV-4) [1,2]. Several clinical
manifestations including plasma leakage, thrombocyto-
penia and hemorrhage, distinguish DHF from DF, which
is a milder infection [2-4]. Severe DHF, also known as
dengue shock syndrome (DSS), can occur when fluid leak-
age into interstitial tissue spaces leads to hypovolemic
shock. Plasma levels of various cytokines such as TNF-α,
IFN-γ and IL-8, were found to be significantly higher in
DHF patients, when compared to DF patients [5]. DENV
infection of target cells in-vitro, induces increased expres-
sion level of these cytokines and other growth factors such
as VEGF. Previous studies have inferred that endothelial
cell damage may also be mediated through effects of
induced VEGF expression in DENV-infected cells [5-8].
These perturbations are thought to at least be partly
responsible for some of the clinical manifestations of
hemorrhage and capillary leakage associated with DHF.
The goal of this study was to quantify secreted VEGF level
in an endothelial cell line that has been infected by all
four serotypes of DENV viruses, at specific time points of
0, 8, 24, 96 and 192 hours post-infection. Human pulmo-
nary microvascular endothelial cell (HPMEC-ST1.6R), an
endothelial cell line generated in 2001, was found to
exhibit most of the phenotypes associated with primary
human microvascular endothelial cells [9]. These cells
that were infected with DENV-1, -2, -3, and -4 viruses as
we had previously described [6], showed cytopathic effect
(CPE) starting from days 1 to 8 post-infection when com-
pared to mock-infected cells (data not shown). The high
titer DENV viruses used in this study were generated in
VERO cells. Various forms of CPE were observed post-
infection including cellular clumping, floating cells sug-
gestive of apoptosis or necrosis, as well as elongated cellu-
lar morphology. In the latter scenario, elongated cells
began to be observed at hour 24 post-infection, and some
cells were seen at a later time point to detach into the cell
medium. The floating and clumping CPE morphology
started to form after 5 days post-infection. The infectivity
of the DENV virions recovered from HPMEC-ST1.6R
infected cells was evaluated using plaque formation assay,
in which monolayers of vero cells were infected with 10-
fold serial dilutions of the tissue culture supernanant, and
the viral plaques were visualized using MTT staining (data
not shown). A real-time RT-PCR analysis of
HPMECST1.6R infected with DENV-1, -2, -3 and -4 were
subsequently performed for quantitative analysis, using
the MXPro3000P (Stratagene). A SYBR Green 1 kit [Strat-
agene] and the DN-F/DN-R primer set [10] were utilized
for amplifications, following instructions specified by the
manufacturer. The DN-F/DN-R primer set which could
bind the templates from all four DENV serotypes, showed
specific amplification (Fig. 1, inset) for all four infected
samples. No amplicon was detected in negative control
sample (no template control, NTC). Following amplifica-
tion, melting curve analysis was performed by raising the
incubation temperature from 62°C to 95°C to verify cor-
rect amplification product by its specific melting temper-
ature. DENV specific products derived from HPMEC-
ST1.6R cells infected with DENV-1 displayed a Tm of
80.7°C, while DENV-2, -3 and -4 displayed specific prod-
ucts with Tm values of 81.8°C, 80.1°C and 81.2°C, respec-
tively (Fig. 1). The RT-PCR analyses provided further
evidence that HPMEC-ST1.6R could be infected by all four
DENV serotypes, as the RNA for these DENV viruses could
be detected in infected cells.
We reported in a previous study that DENV-infected
HPMEC-ST1.6R showed increased levels of specific
cytokines and VEGF, and suggested that the elongated
cytoplasmic morphology in infected cells could be the
result of VEGF-mediated activation of angiogenesis [6]. To
further verify this observation, we quantified the VEGF
levels in the supernatant of DENV-1, -2, -3 and -4 infected
HPMEC-ST1.6R cells at specific time points of 0, 8, 24, 96
and 192 hours post-infection using a microsphere-based
immunoassay which utilized Luminex™ beads coupled to
VEGF-specific antibodies as an analyte capture platform
(BioPlex, Biorad, Hercules, California, USA), essentially
as we had previously described [6]. The reacted beads were
analyzed on a Bio-Plex plate reader; assay controls con-
sisted of beads which were not reacted with sample or
standards, but otherwise treated as previously described.
Standard curves and the concentration of cytokines within
samples were generated through Bio-Plex Manager 4.0
software. Analysis of data was completed using five-para-
metric-curve fitting. Statistical analysis to compare
infected and non-infected culture supernatants included
Students-T test where differences were considered signifi-
cant at P ≤ 0.05. DENV-infected cells showed a higher
level of VEGF when compared to mock-infected cells
(Table 1 and Fig. 2). An interesting display of profile con-
sistent across all four DENV serotypes was observed,
whereby VEGF level increased rapidly 8 hours post-infec-
tion and then hit a plateau at around 96 hours post-infec-
tion. Following this time point, the VEGF levels increased
again, this time significantly up to 192 hours (8 days)
post-infection. The Bio-Plex assay showed a significant (P
≤ 0.05) increase of VEGF in DENV-2-infected cells, when
compared to mock-infected cells for all the time points
analyzed (Table 2). The observed dual profile was repre-
sented by an initial primary increased expression level of
VEGF, followed by a secondary increase in VEGF level.
This could be due to, (1) a direct DENV infection giving
rise to the primary effect of VEGF upregulation, which was
then followed by, (2) the secondary VEGF increased levelPage 2 of 5
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VEGF. We attribute the secondary "burst" of VEGF upreg-
ulation to endothelial cells being in the "primed" state,
which we propose took place after cells were being
exposed to VEGF as well as other cytokines secreted imme-
diately following the DENV-infection. The expression
level of VEGF can be induced by other factors such as FGF-
4, PDGF, TNF-α, TGF-β, insulin-like growth factor 1, IL-
1β, IL-6 and PGE2 [11]. We and others have shown that
expression of some of these cytokines become increased
as a consequence of infection by DENV [5,6,12,13]; these
upregulated cytokines then act on endothelial cells, plac-
ing these cells into the activated "primed" state which in
turn induce secondary increased expression level of VEGF,
as was observed in this study. We envision that in the in-
vivo infection situation, the "primed" endothelial state
would be greatly enhanced due to a cascade of cytokines
secreted by other infected neighboring target cells such
macrophages and dendritic cells [2,4,14], apart from the
endothelial cells. This cytokine effects in turn could result
in vascular leakage-associated immunopathologies asso-
ciated with severe DHF diseases.
Many studies have shown that vascular hyper-permeabil-
ity which can lead to vascular leakage, can occur in
response to a single, brief exposure in the endothelium to
VEGF or other vascular permeabilizing agents [15]. VEGF,
which is the most well-characterized pro-angiogenic
RT-PCR analysis of DENV-1, -2, -3 and 4 infected HPMEC-ST1.6R cellsFigure 1
RT-PCR analysis of DENV-1, -2, -3 and 4 infected HPMEC-ST1.6R cells. Cell culture media of HPMEC-ST1.6R cells 
infected with DENV-1, -2, -3 and -4 were collected and used to obtain total RNA. A real-time RT-PCR analysis of 
HPMECST1.6R cells infected with DENV-1, -2, -3 and -4 were subsequently performed using the extracted RNA for quantita-
tive analysis, using the MXPro3000P [Stratagene]. A SYBR Green 1 kit [Stratagene] and the DN-F/DN-R primer set [10] were 
utilized for amplifications, following instructions specified by the manufacturer. Following amplification, melting curve analysis 
was performed by raising the incubation temperature from 62°C to 95°C to verify correct amplification product by its specific 
melting temperature. DENV specific products derived from Vero or HPMEC cells infected with DENV-1 displayed a Tm of 
80.7°C, while DENV-2, -3 and -4 displayed specific products with Tm values of 81.8°C, 80.1°C and 81.2°C, respectively.Page 3 of 5
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genesis which produces new blood vessels, but also in
stimulating endothelial cell proliferation, migration, dif-
ferentiation, tube formation, increased vascular permea-
bility and maintaining vascular permeability [11].
Endothelial cells infected by another viral agent, Hepatitis
C virus [16], and epithelial cells infected by human rhino-
virus [17] were also shown to induce increased expression
level of VEGF, implicating their roles in mediating immu-
nopathologies associated with these specific viral infec-
tions. Hantaviruses which cause two lethal vascular
permeability-based diseases; hemorrhagic fever with renal
syndromes and hantavirus pulmonary syndromes [18]
was reported to specifically enhance VEGF-directed per-
meabilizing responses in infected endothelial cells. This
particular study implicated a direct role for VEGF in medi-
ating vascular leakage and hemorrhagic diseases in these
Hantaviruses-associated diseases and other vascular leak-
age syndromes.
Severity of plasma leakage in DENV patients was found to
correlate with increased plasma levels of VEGF [8], but
inversely correlated to soluble vascular endothelial
growth factor receptor 2 (sVEGFR2) [7]. Interestingly,
plasma viral load correlated well with a decline of
VEGFR2, which is believed to bind to VEGF, controlling
its availability and interfering with its cellular function.
One proposed implication from this study was that VEGF
participates in regulating vascular permeability that leads
to plasma leakage seen in DHF patients, and that its activ-
ity and availability is controlled by a soluble form of its
receptor, sVEGFR2. A related study which was cited earlier
[18] showed that hantavirus-directed permeability in
infected endothelial cell could be inhibited by antibodies
to VEGFR2, which implicates its therapeutic potential in
the treatment of vascular leakage and hemorrhagic dis-
eases. We have shown in our study that the expression
level of VEGF was elevated in a time-dependent manner,
and exhibited a unique dual-response profile in endothe-
lial cells infected by all four serotypes of DENV viruses.
The experimental observation described here could pro-
vide insights into potential mechanism for VEGF-medi-
ated vascular leakage associated with DENV. Findings
from this and other related studies could provide impetus
to further establish use of anti-VEGFR2 and other poten-
tial anti-VEGF agents [19-21] as therapeutic interventions
for treatment and prevention of vascular leakage associ-
ated with DHF.
VEGF Production in HPMEC-ST1.6R Cells infected with D NV-1, -2, -3, and -4Figure 2
VEGF Production in HPMEC-ST1.6R Cells infected 
with DENV-1, -2, -3, and -4. Monolayers of HPMEC-
ST1.6R cells were infected with either DENV-1, -2, -3 or 
DENV-4 viruses as previously described [6], and incubated at 
37°C in 5% CO2 for 6 days. The cell media of DENV-infected 
cells and mock-infected cells were collected at 0, 8, 24, 96 
and 192 hours post-infection, and analyzed for VEGF produc-
tion [actual values listed in Table 1]. Mean VEGF levels were 
determined using a VEGF analyte detection kit and a BioPlex 
suspension array analyzer from BioRad. Significant increases 
(p ≤ 0.05) in cytokines between virus-infected and mock-
infected cell cultures are given in Table 2. [Bars equal stand-
ard deviation from the mean of triplicates].
Table 1: VEGF levels (pg/ml) ± SD in cell culture conditioned medium of HPMEC-ST1.6R endothelial cells that were infected with 
DENV-1, -2. -3 and -4, or mock-infected [VM(-)] with vero cells culture medium.
Time (Hrs)
Post-infection
VM (-) Mock DENV-1 -infected DENV-2 -infected DENV-3 -infected zDENV-4 -infected
0 0 ± 1.4 0 ± 5.7 0 ± 0.4 0 ± 1.4 0 ± 0
8 1,244.0 ± 1.4 14,997.5 ± 50.2 14,223.8 ± 460.3 21,275.6 ± 550.5 9,094.5 ± 220.6
24 600.1 ± 59.4 10,167.1 ± 384.3 11,039.2 ± 969.4 15,529.7 ± 238.3 11,782.0 ± 53.7
96 876.0 ± 28.6 6,150.6 ± 730.1 10,349.4 ± 189.9 13,541.0 ± 523.6 4,610.1 ± 207.9
192 3,247.7 ± 398.5 25,948.5 ± 432.0 29,889.6 ± 828.4 41,560.4 ± 131.2 20,281.7 ± 706.1
Samples were taken at time points 0, 8, 24, 96, and 192 hours.Page 4 of 5
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DENV-1 -infected DENV-2 -infected DENV-3 -infected DENV-4 -infected
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